Law360, New York (January 26, 2012, 12:31 PM ET) -- Biotech giant Amgen Inc. will purchase cancer specialist Micromet Inc. for $1.16 billion in cash, the buyer announced Thursday, touting a novel tumor treatment as part of the deal.
California-based Amgen said it would pay $11 per share for Maryland-based Micromet, a price unanimously approved by both companies' boards of directors.
"The acquisition of Micromet is an opportunity to acquire an innovative oncology asset with global rights and a validated technology platform with broad potential clinical applications," Amgen CEO Kevin Sharer said.
Amgen said one of...
Sullivan Helps Amgen In $1.2B Micromet Buy
To view the full article, take a free trial now.
